PA

PAVmed Inc

PAVM
Accountable AI Logo

PAVmed Inc AI Insights

Informational only. Not investment advice.
As of 2025-12-16

Snapshot

  • Revenue collapsed 99.5% YoY to 29K TTM with negative gross margin (-524%) - core business essentially non-operational[Total Revenue 1Y Growth]
  • Cash burn of 3.6M TTM against 3.1M cash leaves ~10 months runway without financing[Free Cash Flow TTM]
  • Current debt of 6.9M exceeds current assets of 4.2M; working capital deficit of -6.3M signals near-term liquidity crisis[Working Capital]

Watch Triggers

  • Cash and Equivalents: Falls below 2MWould signal less than 6 months runway, forcing emergency financing at dilutive terms
  • Total Revenue TTM: Exceeds 500K quarterlyWould indicate commercial traction returning; current 29K is essentially zero
  • Issuance of Capital Stock: Material equity raise announcedNecessary for survival but will dilute existing shareholders significantly

Bull Case

P/B of 0.78x below 1.0 suggests market prices in distress; tangible book of 8.5M exceeds 6.6M market cap

P/B RatioTangible Book Value

R&D spend of 3.5M TTM indicates pipeline development continues despite revenue collapse

Research and Development TTM

Bear Case

Negative gross margin (-524%) means every dollar of revenue destroys value; no path to profitability at current scale

Gross Margin TTMOperating Margin TTM

Debt/equity of 1.1x with current debt 2.2x cash creates imminent default risk without refinancing

Debt to EquityCurrent DebtCash and Equivalents

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

BearBull
20%

Leverage PAVM's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

Equity dilution or debt restructuring required within 12 months to avoid insolvency

3-12mhigh
  • Cash runway under 12 months at current burn
  • 6.9M current debt due with 3.1M cash
  • No revenue recovery path visible
FCF -3.6M TTM vs 3.1M cashWorking capital -6.3MRevenue 29K (down 99.5% YoY)
Valuation Context
Caveats

Public Strategies Rankings

See how PAVmed Inc ranks across different investment strategies.

Leverage PAVM's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.

Data Partners
Morningstar Logo

Fundamental company data provided by Morningstar, updated daily.

Accountable Finance, Inc. Disclaimer
accountable.finance is not operated by a broker or a dealer. Under no circumstances does any information posted on accountable.finance represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. In no event shall accountable.finance be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on accountable.finance, or relating to the use of, or inability to use, accountable.finance or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. Stock quotes and fundamental company data provided by Morningstar, updated daily.

Accountable Logo
© 2025 Accountable Finance, Inc. All rights reserved.